Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Conditions
Keywords
oligometastatic melanoma, melanoma
Brief summary
This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic). Stereotactic radiation therapy is a type of external beam radiation therapy that uses special equipment to position the patient and precisely give a either a single large dose of radiation therapy to a tumor or several large doses of radiation therapy to a tumor using precision and accuracy that is guided by onboard daily imaging prior to radiation therapy. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some monoclonal antibodies find tumor cells and help kill them or carry tumor-killing substances to them. Giving stereotactic radiosurgery together with ipilimumab may kill more tumor cells by causing addition melanoma antigens to be presented to the immune system.
Detailed description
PRIMARY OBJECTIVES: I. To determine the progression-free survival of patients with oligometastatic melanoma treated with the combination of stereotactic ablative radiation therapy (SABR) (stereotactic radiosurgery) and ipilimumab in patients with oligometastatic melanoma using modified World Health Organization (mWHO) criteria. SECONDARY OBJECTIVES: I. To evaluate the 6-month progression-free survival of the combination of SABR and 3 mg/kg ipilimumab in patients with oligometastatic melanoma using immune related response criteria (irRC) criteria. II. To evaluate the tolerability and safety of the combination. III. To evaluate the response rate based on mWHO & irRC criteria. IV. To evaluate the local control rate. V. To evaluate the overall survival rate. TERTIARY OBJECTIVES: I. Evaluate changes in blood and serum markers: absolute lymphocyte count, T-cell activation markers, T-cell suppression markers, T-helper cells and related cytokines, T-regulatory (T-reg) markers, co-stimulatory molecules, and serum cytokines when SABR is added to the ipilimumab regimen. II. Evaluate genomic deoxyribonucleic acid (DNA) mutations in key melanoma genes and their correlation with response, progression-free survival, and overall survival. OUTLINE: Patients receive ipilimumab intravenously (IV) over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician. After completion of study treatment, patients are followed up at 30 and 90 days, every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.
Interventions
BIOLOGICALipilimumab
Given IV
RADIATIONstereotactic radiosurgery
Undergo stereotactic radiosurgery
OTHERlaboratory biomarker analysis
Blood and tissue samples will be collected for research purposes.
Sponsors
Bristol-Myers Squibb
Ohio State University Comprehensive Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Willing and able to give written informed consent * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Histologic diagnosis of melanoma with metastatic disease to a visceral organ (lung, liver, brain, adrenal, nodal station outside the regional lymph drainage of the primary, vertebral bodies) * 1-3 sites of metastatic disease able to be targeted by SABR * White blood cells (WBC) \>= 2000/uL * Absolute neutrophil count (ANC) \>= 1000/uL * Platelets \>= 75 x 10\^3/uL * Hemoglobin \>= 9 g/dL (\>= 80 g/L; may be transfused) * Creatinine =\< 2.0 x upper limit of normal (ULN) * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 2.5 x ULN for patients without liver metastasis, =\< 5 times for liver metastases * Bilirubin =\< 2.0 x ULN, (except patients with Gilbert's syndrome, who must have a total bilirubin less than 3.0 mg/dL) * No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C * Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 26 weeks after the last dose of investigational product, in such a manner that the risk of pregnancy is minimized * WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not post-menopausal; post-menopause is defined as: * Amenorrhea \>= 12 consecutive months without another cause, or * For women with irregular menstrual periods and taking hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level \>= 35 mIU/mL * Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (eg, vasectomy) should be considered to be of childbearing potential * WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours before the start of ipilimumab * Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study (and for up to 26 weeks after the last dose of investigational product) in such a manner that the risk of pregnancy is minimized
Exclusion criteria
* Any other malignancy from which the patient has been disease-free for less than 3 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix * Autoimmune disease: patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's disease, are excluded from this study, as are patients with a history of symptomatic disease (eg, rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], systemic lupus erythematosus, autoimmune vasculitis \[eg, Wegener's Granulomatosis\]); motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre syndrome and Myasthenia Gravis) * Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea * Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab) * A history of prior treatment with ipilimumab or prior cluster of differentiation (CD)137 agonist or cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor or agonist * A history of prior treatment with anti-programmed death (PD)-1 or anti-PD-L1 antibodies * Concomitant therapy with any of the following: interleukin (IL)-2, interferon, other non-study immunotherapy regimens, cytotoxic chemotherapy, other investigation therapies * Concomitant therapy with immune-suppressants or chronic use of systemic corticosteroids * Must be off prior systemic therapies for 2 weeks prior to enrollment; patients that have been previously treated with systemic therapy adjuvantly or for metastatic disease remain eligible as long as they continue to meet all other eligibility criteria (oligometastatic, no visceral metastasis \> 5 cm, eligible for SABR) * Prior radiation therapy that at the treating physician's discretion makes SABR unsafe * No evidence of pleural effusion or ascites * Congestive heart failure \> class II New York Heart Association (NYHA) or unstable angina * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * Major surgery, open biopsy or significant traumatic injury within 2 weeks of first dose of study drug * A visceral metastasis greater than 5 cm * A visceral metastasis that due to its location cannot be safely treated with SABR * Women of childbearing potential (WOCBP), defined above who: * Are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for their entire study period and for at least 8 weeks after cessation of study drug, or * Have a positive pregnancy test at baseline, or * Are pregnant or breastfeeding * Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (eg, infectious) illness * Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to study drug, or excipients or to dimethyl sulfoxide (DMSO) * Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 8 weeks after ipilimumab is stopped * Sexually active WOCBP must use an effective method of birth control during the course of the study, in a manner such that risk of failure is minimized; before study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy; all WOCBP MUST have a negative pregnancy test before first receiving ipilimumab; if the pregnancy test is positive, the patient must not receive ipilimumab and must not be enrolled in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Progression-free Survival by mWHO Criteria | Time of study enrollment until the first documented date of disease progression, assessed up to 6 months | Calculated along with corresponding 95% binomial confidence intervals. Kaplan-Meier curves will be used. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Progression-free Survival by irRC Criteria | Time of study enrollment until the first documented date of disease progression, assessed up to 6 months | Calculated along with corresponding 95% binomial confidence intervals. Kaplan-Meier curves will be used. |
| Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Up to 90 days after the last ipilimumab infusion | Frequency and severity of adverse events and tolerability of the regimen in each of the patient groups will be collected and summarized by descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. |
| Frequency of Objective Response Rate, Defined as Complete Response + Partial Response, Measured by Computed Tomography (CT) Using mWHO Criteria | Up to 12 weeks | The response rate evaluated based on mWHO & irRC criteria |
| Rate of Local Failure | Time of study enrollment until the first documented date of failure within the irradiated field, assessed up to 10 years | — |
| Rate of Overall Survival | Time of study enrollment until the time of death, assessed up to 6 years | Kaplan-Meier curves will be used. |
| Frequency of Objective Response Rate, Defined Using irRC | Up to 12 weeks | — |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Marker Levels Between Those With vs. Without the Clinical Improvement | Baseline to week 50 | Summarized univariately in a quantitative manner and also summarized by clinical outcome group (e.g. prog-free and alive at 6 months vs. not). Graphical analyses will be largely used to assess potential patterns and relationships; e.g. side-by-side boxplots to assess differences. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Ipilimumab, Stereotactic Radiosurgery) Patients receive ipilimumab IV over 90 minutes on day 1 in weeks 1, 4, 7, and 10. Treatment repeats every 3 weeks for up to 4 total doses in the absence of disease progression or unacceptable toxicity. At approximately 5-6 weeks, patients undergo stereotactic radiosurgery over 2-3 days per week. Patients with stable disease or confirmed partial or complete response after completion of ipilimumab therapy at week 12 may receive re-induction ipilimumab at the discretion of the treating physician.
ipilimumab: Given IV
stereotactic radiosurgery: Undergo stereotactic radiosurgery
laboratory biomarker analysis: Blood and tissue samples will be collected for research purposes. | 8 |
| Total | 8 |
Baseline characteristics
| Characteristic | Treatment (Ipilimumab, Stereotactic Radiosurgery) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 5 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Region of Enrollment United States | 8 participants |
| Sex: Female, Male Female | 3 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 4 / 8 |
| other Total, other adverse events | 8 / 8 |
| serious Total, serious adverse events | 2 / 8 |
Outcome results
Primary
Rate of Progression-free Survival by mWHO Criteria
Calculated along with corresponding 95% binomial confidence intervals. Kaplan-Meier curves will be used.
Time frame: Time of study enrollment until the first documented date of disease progression, assessed up to 6 months
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Rate of Progression-free Survival by mWHO Criteria | 0.75 months |
Secondary
Frequency of Objective Response Rate, Defined as Complete Response + Partial Response, Measured by Computed Tomography (CT) Using mWHO Criteria
The response rate evaluated based on mWHO & irRC criteria
Time frame: Up to 12 weeks
Population: Data was not collected and analyzed for the study
Secondary
Frequency of Objective Response Rate, Defined Using irRC
Time frame: Up to 12 weeks
Population: Data was not collected and analyzed for the study
Secondary
Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4
Frequency and severity of adverse events and tolerability of the regimen in each of the patient groups will be collected and summarized by descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns.
Time frame: Up to 90 days after the last ipilimumab infusion
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Alanine aminotransferase increased | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Anemia | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Aspartate aminotransferase increased | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Diarrhea | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Generalized muscle weakness | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Hypernatremia | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Hypertension | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Lymphedema | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Musculoskeletal and connective tissue disorder - Other, specify | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Platelet count decreased | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Rash maculo-papular | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Thromboembolic event | 1 Participants |
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Number of Participants With Grade 3 and Grade 4 Toxicities According to Common Toxicity Criteria for Adverse Events (CTCAE) Version 4 | Hyponatremia | 1 Participants |
Secondary
Rate of Local Failure
Time frame: Time of study enrollment until the first documented date of failure within the irradiated field, assessed up to 10 years
Population: Data was not collected and analyzed for the study
Secondary
Rate of Overall Survival
Kaplan-Meier curves will be used.
Time frame: Time of study enrollment until the time of death, assessed up to 6 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Rate of Overall Survival | 0.83 months |
Secondary
Rate of Progression-free Survival by irRC Criteria
Calculated along with corresponding 95% binomial confidence intervals. Kaplan-Meier curves will be used.
Time frame: Time of study enrollment until the first documented date of disease progression, assessed up to 6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Ipilimumab, Stereotactic Radiosurgery) | Rate of Progression-free Survival by irRC Criteria | 0.75 months |
Other Pre-specified
Change in Marker Levels Between Those With vs. Without the Clinical Improvement
Summarized univariately in a quantitative manner and also summarized by clinical outcome group (e.g. prog-free and alive at 6 months vs. not). Graphical analyses will be largely used to assess potential patterns and relationships; e.g. side-by-side boxplots to assess differences.
Time frame: Baseline to week 50
Population: Data not collected and analyzed for the study